Bristol Myers Squibb announced the first presentation of results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo®? (nivolumab) plus Yervoy®? (ipilimumab) compared to investigator's choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).

Results from the study will be featured in a late-breaking oral presentation at the 2024 ASCO Annual Meeting on June 4, at 9:45 a.m. CDT (#LBA4008). With a median follow-up of approximately 35.2 months, treatment with Opdivo plus Yervoy demonstrated: A statistically significant and clinically meaningful improvement in the primary endpoint of overall survival (OS).